Navigation Links
New Study: Lp(a) Joins LDL as Heart Disease Risk Factor
Date:1/19/2010

nd why many people with "normal cholesterol levels" still end up having heart attacks.

Standard cholesterol tests check for levels of LDL (bad cholesterol), HDL (good cholesterol), triglycerides and total cholesterol. Comprehensive lipid testing provided by the VAP Cholesterol Test reports Lp(a) along with other important cholesterol subclasses, non-HDL, emerging heart disease risk factors such as the apoB/apoAI ratio, low-density lipoprotein remnants and small dense LDL as well as triglyceride-rich remnant lipoproteins. The VAP Test also doesn't require fasting and provides a direct measurement of LDL. The VAP Test results may also significantly improve medical treatment for controlling cholesterol levels long before they affect the heart.

Cobble added that in patients with a family history of high cholesterol or early heart attacks, a detailed lipid profile such as the VAP Test may be particularly helpful in diagnosing early problems, including the lack of enough HDL2, HDL3 or too much Lp(a).

The only currently available drug for lowering Lp(a) is niacin, although other drugs are currently in development.

The VAP Test reports 22 separate components of cholesterol, including Lp(a), and is covered by Medicare and most private insurance carriers. Unlike other lipid profiles, the VAP Test includes Lp(a) at no additional charge, and it directly measures all three lipoprotein parameters — LDL, non-HDL and apoB — considered necessary by the expert consensus guidelines issued by the American Diabetes Association and American College of Cardiology. The VAP Test identifies a far greater number of people at risk for heart disease than standard cholesterol tests and is the only single cholesterol test that routinely reports apoAI, apoB and the apoB/apoAI ratio.

People with a family history or an existing condition of diabetes, high blood pressure or heart disease — or who are already taking c
'/>"/>

SOURCE Atherotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Study: Era of Rapid Growth in Biomedical Research Over
2. Penn study: Transforming nanowires into nano-tools using cation exchange reactions
3. Kline Study: Better Brushing Habits Boost European Oral Care Sales
4. Attorney Wayne Keown Joins Preti Flaherty's Portland, ME Office
5. New Director of Bioanalytical Services Joins Toxikon
6. The Honorable Tommy G. Thompson Joins the United Therapeutics Corporation Board of Directors
7. Dennis Winger Joins Nektar Therapeutics Board of Directors
8. Rosalie Dunn, Ph.D., Joins Gwathmey, Inc. as Chief Executive Officer
9. Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner
10. Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer
11. Richard T. Crowder Joins Neogens Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , ... July 29, 2015 , ... The third Medical ... combination products , in particular, drug/device combinations. The current system received a score ... Initiative for Patient Centered Innovation (iPCI) of Fairleigh Dickinson University’s ( FDU ...
(Date:7/29/2015)... ... July 29, 2015 , ... Available ... NIGHT Express Contouring Bi-Gel, a nighttime-specific product that targets fat cells for extreme ... are able to enter fat cells, inhibiting the formation of new fat. Upon ...
(Date:7/28/2015)... A n ew UK company ... commercialising innovative medicines to transform patient quality of life and ... team; blue chip investor ... Ltd ("Mereo"), a recently-formed speciality biopharmaceutical company, announces that it ... blue chip institutional investors and simultaneously acquired a portfolio of ...
(Date:7/28/2015)... July 28, 2015 Seahorse Bioscience, the ... is the provider of XF Technology which is ... research areas. As the links between mitochondrial function ... metabolism is escalating rapidly.   Recently, ... Nature Publishing Group (NPG) featuring XF Technology, including ...
Breaking Biology Technology:Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 2Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 5Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 6Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 7Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 8Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 9Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 10Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 11XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique 2XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique 3
... Aton Pharma, Inc., a,global specialty pharmaceutical company, ... management board of Aton,s parent company,Princeton Pharma Holdings ... CEO of Pharmaceutical Product Development, Inc. (Nasdaq: ... a wholly owned,subsidiary of Princeton Pharma Holdings LLC., ...
... LAKE, N.J., Feb. 25 Strativa,Pharmaceuticals, the proprietary ... Pharmaceutical Companies, Inc. (NYSE: PRX ) today,announced ... IMM ) has chosen to discontinue the development ... February 22, 2008, Immtech announced that it had ...
... Idenix,Pharmaceuticals, Inc., (Nasdaq: IDIX ) announced today ... quarter of 2007 on Thursday, March 6,2008 after the ... issuance of the press release, Idenix,management will host a ... 2008 to discuss the company,s financial results for the ...
Cached Biology Technology:Aton Pharma Announces the Appointment of Dr. Fred Eshelman to Management Board 2Strativa Pharmaceuticals, a Division of Par Pharmaceutical, Announces the Discontinuation of the Development Program for Pafuramidine 2Strativa Pharmaceuticals, a Division of Par Pharmaceutical, Announces the Discontinuation of the Development Program for Pafuramidine 3
(Date:7/13/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... on the growing mobile commerce market, announced today ... BEHAVIORAL-DIRECTED AUTHENTIATION METHOD AND SYSTEM. ... method to make payments.  With this patent, NXT-ID ... its groundbreaking voice-direct payment patent application, with behavior-directed ...
(Date:7/8/2015)... , July 8, 2015 Summary Pancreatic ... the fourth most fatal, with a mortality rate of ... prognosis of pancreatic cancer patients has highlighted a significant ... is not being met by the current market. ... of products with varying molecule types and mechanisms of ...
(Date:7/7/2015)... , July 7, 2015  Based on its ... & Sullivan recognizes Credence ID, LLC with the ... Company of the Year Award. Credence ID has ... in its mission of offering enrollment and identification ... As Credence ID was formed by experts from ...
Breaking Biology News(10 mins):NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5
... cure for a fungus and parasite that affects millions of ... Missouri Chemistry Professor John Tanner would be the forensic expert ... that could eventually solve the crime. Tanner, who also teaches ... forces with Pablo Sobrado, an assistant professor of biochemistry at ...
... Illinois chemists have developed a simple sensor to detect ... to inexpensive, easy-to-use devices for luggage and passenger screening ... a high-powered explosive that in recent years has been ... prepare from readily available components and has been difficult ...
... Adelaide have discovered new cases of herbicide resistance ... and costly weeds. For the first time, researchers ... paraquat, the second most important "knockdown" herbicide used by ... and Associate Professor Christopher Preston, from the University,s Waite ...
Cached Biology News:X-ray diffraction may play key role in stopping 'kissing bug,' fungus 2Sniffing out shoe bombs: A new and simple sensor for explosive chemicals 2
Whole blood is collected from healthy pigs (mixed breed, either sex) at the time of slaughter, refrigerated within 6 hours, processed within 24 hours and frozen at -20ºC....
Human/Mouse/Rat Keap1 MAb (Clone 333116) Protein Family: Transcription Factor Regulators...
Collected from sexually mature, mixed sex, mixed breed guinea pigs. Pricing: $120/unit for 1 - 10 units...
... Kit, Protein, 1. Based on the ... the kit gives essentially colorless backgrounds ... Kit, Protein provides convenient, reproducible and ... gels in less than two hours.The ...
Biology Products: